CrossrefInfokarte
Reframing metabolic dysfunction-associated steatotic liver disease via the cardio-hepatic axis: Phenotype-guided incretin and sodium-glucose cotransporter 2 inhibitor therapy
World Journal of Cardiology · 2026-11-05
DOI: 10.4330/wjc.127591 ↗Abstract
Kein Abstract verfügbar.
EUVIMED